Delving into the Latest Updates on Aztreonam with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Aztreonam (JP17/USP/INN), E0734, NSC-646279

+ [7]

Target

PBPs

Action

inhibitors

Mechanism

PBPs inhibitors(Bacterial penicillin-binding protein inhibitors)

Therapeutic Areas

Infectious DiseasesNervous System DiseasesCongenital Disorders+ [7]

Active Indication

Cystic FibrosisBacterial InfectionsGram-Negative Bacterial Infections+ [32]

Inactive Indication

Infectious Lung DisorderPseudomonas InfectionsSkin Diseases, Infectious

Originator Organization

Bristol Myers Squibb Co.

Active Organization

Laboratoires Delbert SAS

Meiji Seika Pharma Co., Ltd.

Eisai Co., Ltd.

+ [2]

Inactive Organization

Pfizer Inc.Huizhi Pharmaceutical (Dalian) Co., Ltd.Wyeth AB

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (31 Dec 1986),

AbscessGynecological infectionInfectious Diseases+ [4]

RegulationOrphan Drug (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC13H17N5O8S2

InChIKeyWZPBZJONDBGPKJ-VEHQQRBSSA-N

CAS Registry78110-38-0

This is a multicenter stepped-wedge cluster randomized trial, conducted over a 2-year period at three hospitals. The trial is structured into four phases, each lasting six months. During phase 1 (pre-rollout), all hospitals will use standard antibiotic prophylaxis for all patients. In each of phases 2 to 4, one hospital will switch to targeted antibiotic prophylaxis, so that by phase 4 all hospitals will be using it. The order in which hospitals switch is determined by computer-generated randomization performed centrally by an independent statistician, ensuring each hospital has an equal chance of switching at any given phase and minimizing selection bias.
The goal of this clinical trial is to learn whether targeted antibiotic prophylaxis works better than standard antibiotic prophylaxis at preventing infections in liver transplant patients who carry resistant bacteria called CPE (carbapenemase-producing Enterobacterales). It will also learn about the effects of these antibiotics on gut bacteria.
The main questions it aims to answer are:
* Does targeted antibiotic prophylaxis reduce the number of CPE infections occurring in the first two weeks after liver transplant, compared to standard prophylaxis?
* How do targeted and standard antibiotic prophylaxis affect the gut microbiome after transplant?
* Is there a link between achieving optimal antibiotic blood levels and the risk of developing an infection after transplant?
Researchers will compare targeted antibiotic prophylaxis (chosen based on the specific bacteria each patient carries) to standard antibiotic prophylaxis (used routinely at each hospital) to see which approach better prevents infection.
This study does not involve the administration of any drugs or instrumental examinations beyond those already part of standard clinical care at each center. However, additional blood tests will be performed by collecting one extra blood sample (and a bile sample, if the patient has a Kehr's tube, which is a drain placed in the bile duct after surgery) during blood draws already scheduled as part of routine clinical practice, in order to measure drug levels in the blood. Stool samples will also be collected specifically for the study to investigate the gut microbiome.

Start Date01 Oct 2026

Sponsor / Collaborator

IRCCS Azienda Ospedaliero-Universitaria di Bologna

NCT07478484

/ RecruitingPhase 4IIT

A Clinical Study on Sequential Infusion Versus Concomitant Infusion of Ceftazidime-avibactam Combined With Aztreonam for the Treatment of Metallo-β-lactamase-producing Carbapenem-resistant Gram-negative Bacterial Infections.

Metallo-β-lactamase-producing carbapenem-resistant Gram-negative bacteria (MBL-CR-GNB), due to their capacity to hydrolyze almost all β-lactam antibiotics, have become a critical global threat in antimicrobial resistance. Current novel β-lactamase inhibitors (e.g., avibactam, relebactam, vaborbactam) only inhibit serine enzymes and are ineffective against metallo-β-lactamases (MBL), severely limiting clinical treatment options. Aztreonam (ATM) is inherently stable against MBL, while avibactam (AVI) inhibits co-produced serine β-lactamases (e.g., KPC, OXA-48). Their combination achieves complementary synergistic antibacterial effects. The ceftazidime-avibactam plus aztreonam (CZA+ATM) regimen, operating via the mechanism of "avibactam protecting aztreonam", has demonstrated synergistic bactericidal activity against NDM, VIM, IMP and other MBL-producers in multiple real-world and clinical studies, significantly reducing infection-related mortality.However, although current domestic and international guidelines recommend the CZA+ATM combination for MBL infections, there is no consensus on optimal infusion strategies. Based on the above, this study hypothesizes that in patients with complicated infections caused by MBL-producing CR-GNB, different infusion modalities of ceftazidime-avibactam combined with aztreonam-concomitant infusion versus sequential infusion-will show no significant differences in PK/PD target attainment rates, clinical cure rates, microbiological eradication rates, or all-cause mortality, without increasing the risk of adverse events.

Start Date31 Mar 2026

Sponsor / Collaborator

Third Affiliated Hospital of Nanjing Medical University

CTIS2024-516232-10-00

/ Not yet recruitingPhase 4IIT

Defining Antibiotic Levels in Intensive care patients (DALI-2) protocol - A multi-national pharmacokinetic/pharmacodynamic cohort study to determine whether contemporary antibiotic dosing for critically ill patients achieves therapeutic exposures.

Start Date01 Dec 2025

Sponsor / Collaborator

Centre Hospitalier Universitaire de Nimes

100 Clinical Results associated with Aztreonam

Login to view more data

100 Translational Medicine associated with Aztreonam

Login to view more data

100 Patents (Medical) associated with Aztreonam

Login to view more data

7,523

Literatures (Medical) associated with Aztreonam

31 Dec 2026·Emerging Microbes & Infections

Spread of carbapenemase-producing Serratia spp. in France from 2016 to 2024: a comparative genomic study

Article

Author: Jousset, Agnès B. ; Emeraud, Cécile ; Bonnin, Rémy A. ; Larouy-Maumus, Gerald ; Dortet, Laurent ; Ouacel, Kenza ; Rezzoug, Inès ; Bernabeu, Sandrine ; Birer, Aurelien

Carbapenemase-producing Serratia spp. are increasingly implicated in healthcare-associated infections. This study aimed to characterize the genetic diversity, resistance mechanisms, and susceptibility to last resort antimicrobials of carbapenem-resistant Serratia spp. in France. From 2016 to 2024, 193 carbapenemase-producing Serratia spp. from France were investigated. WGS enabled species identification, MLST typing, resistome characterization and phylogenetic analysis. Antimicrobial susceptibility was assessed by broth microdilution, focusing on last resort antimicrobials. Intrinsic resistance to polymyxins was explored by genomic analysis and lipid A mass spectrometry. S. sarumanii (54%) and S. nevei (41%) dominated the epidemiology while no S. marcescens was identified. The most prevalent carbapenemases were OXA-48-like (56%), NDM (25%), IMP (8%), and VIM (7%). MLST identified 67 sequence types (ST) with 42% of the isolates belonging to four high-risk clones: ST-601, ST-298, ST-477, ST-600 and ST-474. β-lactamse susceptibility was low, but aztreonam-avibactam remained highly active (98%). Intrinsic resistance to polymyxin did not result from lipid A modifications as reported for Proteae. In France, carbapenemase-producing Serratia spp. were dominated by S. sarumanii and S. nevei. The absence of S. marcescens, the genus leader, highlighted the need to update the MALDI-TOF database. This study highlights Serratia as an underestimated reservoir of multidrug resistance.

01 Dec 2026·MOLECULAR BIOLOGY REPORTS

Prevalence of quorum sensing luxS gene in multidrug resistant uropathogens

Article

Author: Kotturu, Sandeep Kumar ; Ghosh, Soham ; Pradhan, Shilpa ; Lakshmi, Swarajya ; Mukhopadhyay, Sangita

BACKGROUND:

The increasing prevalence of antimicrobial resistance (AMR) among urinary tract infections (UTIs) is making clinical management challenging. Biofilm formation is a key mechanism contributing to antibiotic resistance in uropathogens. Quorum sensing is known to regulate several bacterial processes like bioluminescence, virulence, and biofilm formation which is known to play a role in the development of drug resistance. Out of three major quorum sensing systems, luxS/AI-2 is a universal system used by both Gram-positive and Gram-negative bacteria.

METHODS:

Community-acquired AMR UTI isolates were analyzed for bacterial species distribution and antibiotic susceptibility patterns. Phenotypic biofilm formation was assessed using Congo Red Agar (CRA) method. The presence of luxS gene, associated with the AI-2 quorum sensing system, was determined by polymerase chain reaction (PCR).

RESULTS:

Eight different bacterial species were identified, with Escherichia coli (44.1%) being the most prevalent, followed by Klebsiella spp. (27.9%). More than 90% of the isolates were resistant to at least 3 antibiotics and resistance to ampicillin was most common (67.6%), followed by cefazolin (54.4%), amoxyclav (53.4%), aztreonam (52.9%), and ciprofloxacin (48.52%). Phenotypic biofilm formation was observed in 35.29% of the AMR isolates which produced characteristic black colonies. However, luxS gene was detected in 91.17% of these AMR isolates.

CONCLUSION:

Higher prevalence of luxS gene in AMR isolates indicate a strong association of quorum sensing potential with development of multidrug resistance. Targeting quorum sensing pathways may represent potential adjunct therapy alongside antibiotics for efficient clinical management of multidrug resistant UTI cases.

01 Dec 2026·MOLECULAR BIOLOGY REPORTS

High prevalence and co-existence of SHV and CTX-M genes in extensively drug-resistant (XDR) Gram-negative bacteria isolated from hospital settings in Faisalabad District, Pakistan

Article

Author: Shaukat, Amir ; Duarte, Tania Da Silva ; Sattar, Azfar ; Blaskovich, Mark A T ; Zuegg, Johannes ; Ahmad, Zaheer ; Ali, Aamir ; Sarwar, Yasra ; Shehzad, Khurram ; Abbas, Umair ; Sajjad, Huma

BACKGROUND: Hospital-acquired infections (HAIs) associated with increasing antimicrobial resistance (AMR) are becoming a global health challenge, causing AMR spread and a serious health threat. This study was designed to evaluate the phenotypic and genotypic status of AMR in Gram-negative HAI-associated bacteria, to gain a current insight into the local settings. METHODS AND RESULTS: Kirby-Bauer method and Double Disc Synergy Test were used for phenotypic assessment of AMR and extended-spectrum β-lactamase (ESBL) producers, respectively. Genes encoding antimicrobial resistance, ESBLs, and carbapenemases were identified by PCR followed by Sanger sequencing. Among 102 HAI samples, 62 were Gram-negative, identified as Escherichia coli (E. coli) (42.2%), Klebsiella pneumoniae (K. pneumoniae) (21.1%), and Pseudomonas aeruginosa (P. aeruginosa) (6.6%) by PCR. All K. pneumoniae and (95%) E. coli isolates exhibited multidrug resistance. K. pneumoniae isolates (95%) showed resistance against ceftazidime, cefotaxime, ceftriaxone, and aztreonam, and (89%) isolates were resistant to amoxicillin-clavulanic acid, ofloxacin, and cefepime (E. coli isolates (84%), (84%), (78%), (76%), (76%), and (73%) were resistant against cefotaxime, ceftriaxone, aztreonam, ceftazidime, doripenem, and colistin, respectively. Genotypically, the mcr-2 gene was detected in 5% K. pneumoniae isolates. Phenotypically, 63% isolates were identified as ESBL producers with high genetic prevalence of SHV-12 (78.9%) and SHV-1 (57.8%) in K. pneumoniae and CTX-M1 (60.5%) in E. coli. Notably, one K. pneumoniae isolate harbored all class-A ESBL genes, which is a novel finding. Co-existence of CTX-M1 + SHV-1 + TEM-1, SHV-1 + SHV-12 + TEM-1, and CTX-M1 + CTX-M15 + TEM-1 genes was dominant. CONCLUSION: The HAIs caused by extensively drug-resistant and ESBL-producing K. pneumoniae and E. coli were dominant, with less prevalence of moderately drug-resistant Pseudomonas isolates.

59

News (Medical) associated with Aztreonam

30 Jul 2026

·www.biospace.com

Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 2026

TOKYO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe ’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe ’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study ( jRCT2031230076 ) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatment success at seven days after the end of treatment, cefepime/nacubactam and aztreonam/nacubactam showed success rates of 44.4% (12/27 patients) and 50.0% (12/24 patients), respectively; for reference, the success rate with Best Available Therapy (BAT) was 26.1% (6/23 patients). No major clinical safety concerns were observed. For background, nacubactam is a β-lactamase inhibitor intended for use in combination with cefepime or aztreonam for infections caused by Gram-negative bacteria resistant to carbapenems. Based on the results of two Phase III global studies—the Integral-1 study (enrolling patients with complicated urinary tract infections and acute uncomplicated pyelonephritis; jRCT2031230075 ) and the Integral-2 study (enrolling patients with infections caused by carbapenem-resistant Enterobacterales [CRE]; jRCT2031230076 )—Meiji Seika Pharma submitted a New Drug Application (NDA) in Japan in December 2025. ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); Meiji Seika Pharma is committed to contributing to the fight against antimicrobial resistance (AMR), a global issue known as the silent pandemic. About Nacubactam (Development Code: OP0595): Nacubactam is a novel β-lactamase inhibitor developed by Meiji Seika Pharma. When used in combination with approved β-lactam antibiotics, it is expected to be effective against CRE. This mechanism restores the antimicrobial activity of β-lactam antibiotics against CRE. Additionally, OP0595 inhibits penicillin-binding protein 2 (PBP2), an enzyme involved in the biosynthesis of peptidoglycan, a key component of bacterial cell walls. This additional mechanism enhances the antimicrobial activities of β-lactam antibiotics against CRE. This dual mechanism differentiates it from existing β-lactamase inhibitors. References: Venkatesan P. ESCMID Global Congress 2026. The Lancet Microbe. 2026:101476. Contacts For further information: Meiji Seika Pharma Co., Ltd. Hayato Okade Project Manager, Nacubactam pr-pharma@meiji.com

14 May 2026

·www.biospace.com

Meiji Seika Pharma: Positive Results from the Phase III Integral-1 Trial of Nacubactam, a Novel β-Lactamase Inhibitor, in Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis ― Published in The Lancet

TOKYO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo; President and Representative Director: Toshiaki Nagasato) today announced that the results of the Integral-1 study, one of two global Phase III clinical trials evaluating the efficacy and safety of its novel β-lactamase inhibitor nacubactam (development code: OP0595), have been published in The Lancet . The article is entitled “---Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with imipenem–cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial” ( (26)00596-9/fulltext ) Integral-1 is a global, double-blind, randomized Phase III trial (jRCT2031230075) in patients with complicated urinary tract infection or acute uncomplicated pyelonephritis that compared the efficacy and safety of nacubactam co-administered with either cefepime or aztreonam versus imipenem-cilastatin, a carbapenem. The study met its primary endpoint of composite clinical and microbiological response seven days after the end of treatment, demonstrating non-inferiority of cefepime-nacubactam to imipenem-cilastatin. Superiority of cefepime-nacubactam over imipenem-cilastatin and non-inferiority of aztreonam-nacubactam versus the same comparator were demonstrated. With respect to safety, the incidence of adverse events was comparable between groups, and no new safety concerns were identified. Although not covered in this article, positive results were also observed in Integral-2, the other Phase III trial (jRCT2031230076) that enrolled patients with infections caused by carbapenem-resistant Enterobacterales (CRE). These results were presented at ESCMID Global 2026, and a manuscript is in preparation. Carbapenem-resistant Gram-negative bacteria pose a global threat as carbapenems are among the last-resort options for severe infections. Effective agents against multidrug-resistant Gram-negative pathogens, including CRE, are urgently needed. To help address this need, in December 2025, Meiji Seika Pharma submitted an application in Japan for manufacturing and marketing approval of nacubactam and remains committed to contributing to global efforts against antimicrobial resistance (AMR)—the “silent pandemic.” About nacubactam (development code: OP0595): Nacubactam is a novel β-lactamase inhibitor discovered by Meiji Seika Pharma. In combination with existing β-lactam antibiotics, nacubactam is expected to be effective against carbapenem-resistant Enterobacterales (CRE). In addition, nacubactam inhibits penicillin-binding protein 2 (PBP2), an enzyme involved in the biosynthesis of peptidoglycan in the bacterial cell wall, the mechanism that distinguishes it from other β-lactamase inhibitors. Contacts For further information: Meiji Seika Pharma Co., Ltd. Hayato Okade Project Manager, Nacubactam pr-pharma@meiji.com

Phase 3Clinical ResultQualified Infectious Disease Product

15 Apr 2026

·www.biospace.com

Meiji Seika Pharma’s Nacubactam to Be Featured in 10 Presentations at ESCMID Global 2026 — Including Phase III Integral-2 Results

TOKYO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo; President and Representative Director: Toshiaki Nagasato) today announced that at ESCMID Global 2026, to be held from 17 to 21 April 2026, it will present a total of ten studies on its novel β-lactamase inhibitor nacubactam (development code: OP0595), for which a manufacturing and marketing authorisation application is under review in Japan. The presentations include results from Integral-2, an international, multicentre Phase III clinical trial in patients with infections due to carbapenem-resistant Enterobacterales (CRE). Currently, carbapenem-resistant bacteria pose a global threat because carbapenems are considered last-resort agents for severe infections. The development and approval of effective agents against multidrug-resistant Gram-negative bacteria, including CRE, are urgently needed ( WHO Bacterial Priority Pathogens List, 2024 ). In December 2025, Meiji Seika Pharma submitted an application for manufacturing and marketing approval of nacubactam in Japan and remains committed to contributing to global efforts against AMR—the “silent pandemic.” The planned presentations are as follows: Efficacy and safety of cefepime/nacubactam and aztreonam/nacubactam vs best available therapy in adults with cUTI/AP, HABP/VABP, cIAI due to carbapenem resistant Enterobacterales: Integral-2, single-blind, randomised phase III trial — Oral presentation (O0107); Clinical Outcomes of cefepime/nacubactam and aztreonam/nacubactam for treatment of cUTI/AP patients with CRE: subgroup analysis of Integral-1 study — Poster (P2876); Poster Walkthrough (R0058); Clinical Outcomes of cefepime/nacubactam and aztreonam/nacubactam in cUTI/AP patients with ESBL-producing bacteria enrolled into prospective phase III randomised clinical study (Integral-1) — Poster (P2864); Clinical Efficacy and safety of cefepime/nacubactam and aztreonam/nacubactam compared with imipenem/cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis: Integral-1, a double-blind, randomised phase III trial — Poster (P2857); Clinical The in vitro activity of aztreonam/nacubactam and cefepime/nacubactam against molecularly characterised Enterobacterales isolates including those with ceftazidime-avibactam and aztreonam/avibactam resistance mechanisms collected globally from 2021–2023 — Top Rated Poster (P1622); Non-clinical Activity of the novel combination therapy cefepime/nacubactam against 17,220 clinical isolates of Enterobacterales collected worldwide during 2021–2024 — Poster (P1197); Non-clinical In vitro activity of nacubactam against broad-spectrum β-lactamases — Poster (P2659); Non-clinical Probability of target attainment of cefepime/nacubactam and aztreonam/nacubactam for carbapenem-resistant Enterobacterales infections — Poster (P2742); PK/PD Population pharmacokinetic analysis of nacubactam, cefepime, and aztreonam and exposure–response analysis of efficacy results from phase III clinical trials — Poster (P2743); PK/PD Determination of the nonclinical PK/PD target value for nacubactam in a mouse thigh infection model using carbapenem-resistant Enterobacterales under co-administration of cefepime or aztreonam — Poster (P2744); PK/PD Following congress selection, O0107 was chosen for an Oral Presentation, P2876 for the Poster Walkthrough session, and P1622 as a Top Rated Poster (top 2%). About nacubactam (development code: OP0595) Nacubactam (development code: OP0595) is a novel β-lactamase inhibitor discovered by Meiji Seika Pharma. In combination with existing β-lactam antibiotics such as cefepime or aztreonam, nacubactam is expected to be effective against carbapenem-resistant Enterobacterales (CRE), including carbapenemase-producing strains. In addition, nacubactam inhibits penicillin-binding protein 2 (PBP2), an enzyme involved in the biosynthesis of peptidoglycan in the bacterial cell wall, thereby conferring a property that distinguishes it from other β-lactamase inhibitors. In the Integral-1 trial, for the primary endpoint of composite clinical and microbiological response at seven days after the end of treatment, superiority of cefepime/nacubactam over imipenem/cilastatin and non-inferiority of aztreonam/nacubactam to the same comparator were demonstrated. With respect to safety, no significant safety concerns were observed (press release dated 14 March 2025). In the Integral-2 trial, for the primary endpoint of overall composite response at seven days after the end of treatment across all enrolled indications, high efficacy of both cefepime/nacubactam and aztreonam/nacubactam was confirmed compared with best available therapy. With respect to safety, no significant safety concerns were observed. Contacts For further information: Meiji Seika Pharma Co., Ltd. Hayato Okade Project Manager, Nacubactam pr-pharma@meiji.com

100 Deals associated with Aztreonam

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00240	Aztreonam	J01DF01	DB00355

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Cystic Fibrosis	United States	Gilead Sciences, Inc.	22 Feb 2010
Bacterial Infections	United States	Laboratoires Delbert SAS	22 Jan 2008
Gram-Negative Bacterial Infections	China	Sino-American Shanghai Squibb Pharmaceuticals Ltd.	01 Jan 1997
Intraabdominal Infections	United States	Laboratoires Delbert SAS	01 Nov 1996
Meningitis	Japan	Meiji Seika Pharma Co., Ltd.	31 May 1988
Meningitis	Japan	Eisai Co., Ltd.	31 May 1988
Abdominal Abscess	Japan	Meiji Seika Pharma Co., Ltd.	12 Jan 1987
Abdominal Abscess	Japan	Eisai Co., Ltd.	12 Jan 1987
Cholangitis	Japan	Eisai Co., Ltd.	12 Jan 1987
Cholangitis	Japan	Meiji Seika Pharma Co., Ltd.	12 Jan 1987
Cholecystitis	Japan	Eisai Co., Ltd.	12 Jan 1987
Cholecystitis	Japan	Meiji Seika Pharma Co., Ltd.	12 Jan 1987
Cystitis	Japan	Eisai Co., Ltd.	12 Jan 1987
Cystitis	Japan	Meiji Seika Pharma Co., Ltd.	12 Jan 1987
Hemorrhagic Septicemia	Japan	Eisai Co., Ltd.	12 Jan 1987
Hemorrhagic Septicemia	Japan	Meiji Seika Pharma Co., Ltd.	12 Jan 1987
Intrauterine infection	Japan	Eisai Co., Ltd.	12 Jan 1987
Intrauterine infection	Japan	Meiji Seika Pharma Co., Ltd.	12 Jan 1987
Keratitis	Japan	Eisai Co., Ltd.	12 Jan 1987
Keratitis	Japan	Meiji Seika Pharma Co., Ltd.	12 Jan 1987

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Carbapenem Resistant Bacterial Infection	Phase 3	United States	Meiji Seika Pharma Co., Ltd.	22 Sep 2023
Carbapenem Resistant Bacterial Infection	Phase 3	China	Meiji Seika Pharma Co., Ltd.	22 Sep 2023
Carbapenem Resistant Bacterial Infection	Phase 3	Japan	Meiji Seika Pharma Co., Ltd.	22 Sep 2023
Carbapenem Resistant Bacterial Infection	Phase 3	Croatia	Meiji Seika Pharma Co., Ltd.	22 Sep 2023
Carbapenem Resistant Bacterial Infection	Phase 3	Czechia	Meiji Seika Pharma Co., Ltd.	22 Sep 2023
Carbapenem Resistant Bacterial Infection	Phase 3	France	Meiji Seika Pharma Co., Ltd.	22 Sep 2023
Carbapenem Resistant Bacterial Infection	Phase 3	Greece	Meiji Seika Pharma Co., Ltd.	22 Sep 2023
Carbapenem Resistant Bacterial Infection	Phase 3	Israel	Meiji Seika Pharma Co., Ltd.	22 Sep 2023
Carbapenem Resistant Bacterial Infection	Phase 3	Latvia	Meiji Seika Pharma Co., Ltd.	22 Sep 2023
Carbapenem Resistant Bacterial Infection	Phase 3	Slovakia	Meiji Seika Pharma Co., Ltd.	22 Sep 2023

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05887908 (Integral-1, Pubmed \| Lancet)	Phase 3	Acute pyelonephritis \| Complicated urinary tract infection	614	Cefepime-nacubactam	rsztjovlci(qnhavwufwc) = aubrkhlcht kzgalmdnvm (cwentxmowx ) View more	Positive	01 May 2026
NCT05887908 (Integral-1, Pubmed \| Lancet)	Phase 3	Acute pyelonephritis \| Complicated urinary tract infection	614	Aztreonam-nacubactam	rsztjovlci(qnhavwufwc) = nleinlsnbq kzgalmdnvm (cwentxmowx ) View more	Positive	01 May 2026
NCT05887908 (Integral-1, CTgov)	Phase 3	Acute pyelonephritis \| Ectodermal Dysplasia \| Complicated urinary tract infection	614	imipenem/cilastatin	xbppfgwjdk = etjfgpehud szbjnnozlf (dkvjomnouc, pmipwhjxez - ytfloqfjti) View more	-	25 Nov 2025
NCT03978091 (Pubmed) Manual	Phase 1	-	19	Aztreonam+Ceftazidime+Avibactam	qyfdumnqbt(shhkxuchuc) = xhjsswbnrj joyyhlobgm (ruxuqjljms ) View more	Positive	17 Nov 2022
NCT03867734 (CTgov)	Phase 2/3	Gonorrhea \| Gonococcal urethritis \| Pharyngeal Diseases	32	Aztreonam	ugkmustumo(ahmrbtedzr) = ubfhrvqgjx btcensaetf (mdqxeigypq, brssjtepzt - krulgkpghe) View more	-	06 Jan 2022
NCT03978091 (CTgov)	Phase 1/2	Bacterial Infections	48	AVYCAZ IV (AVYCAZ IV)	gzdkrijqkx = pfnvqfmwam gkqoazreyo (tcynrzzuyh, xklzcppayu - lgzhkvsbnm) View more	-	23 Dec 2021
NCT03978091 (CTgov)	Phase 1/2	Bacterial Infections	48	AVYCAZ (AVYCAZ CI)	gzdkrijqkx = nvgeaimmlg gkqoazreyo (tcynrzzuyh, cjkbkvenij - aleccdvqxv) View more	-	23 Dec 2021
NCT03158116 (A-PACT, CTgov)	Phase 4	Infectious Diseases	5	Inhaled Aztreonam	ttaiugyqdh = ykyembisnz aldplzhcjr (mknjariqxc, pzewxemhva - rlzmpnsrja) View more	-	30 Jul 2021
NCT02730793 (CTgov)	Phase 2	Nose Diseases \| Cystic Fibrosis	5	Nasal Placebo+Oral Aztreonam (Standard Therapy)	uqrjiukbvk(wfgepsbjko) = awfwqmgrce veydpxhbmp (ircbgwlfct, oovdugtrmv - vvpejcsgud) View more	-	12 Jan 2021
NCT02730793 (CTgov)	Phase 2	Nose Diseases \| Cystic Fibrosis	5	Oral Aztreonam (Study Therapy)	uqrjiukbvk(wfgepsbjko) = kmlqcchhxc veydpxhbmp (ircbgwlfct, xgdmbouyfn - ovhmlrbsee) View more	-	12 Jan 2021
NCT03867734 (Pubmed \| Antimicrob Agents Chemother)	Phase 2/3	Gonorrhea	32	Aztreonam 2g	ckvppctiiq(krseovcopk) = msnffchgut btwwkftjty (xisusmbpsb ) View more	-	16 Dec 2020
NCT01659866 (CTgov)	Phase 4	Infectious Diseases	563	Ciprofloxacin (Cipro-susceptible)	wzlmpzizhs = njkttyrllc lnqsgtdlpg (qshaegtbod, qicwqbrucb - gznglmkgcu) View more	-	25 Jun 2019
NCT01659866 (CTgov)	Phase 4	Infectious Diseases	563	imipenem+aztreonam+trimethoprim-sulfamethoxazole+cefuroxime+gentamicin+ceftriaxone+amikacin (Cipro-resistant)	wzlmpzizhs = jwjbsurbli lnqsgtdlpg (qshaegtbod, eyttmchmdx - qpxvkikpek) View more	-	25 Jun 2019
NCT01375049 (ALPINE, Pubmed \| J Cyst Fibros)	Phase 2	Cystic Fibrosis	105	Aztreonam for inhalation solution (AZLI) 75 mg	xnbonjbgfs(qigqeacmkq) = ryolqibrez pvyjxnykai (lrwgsnqobf )	-	01 Jan 2015